Star Health & Allied Insurance Downgraded to Strong Sell Amid Weak Financials and Bearish Technicals

Quality Assessment: Mixed Fundamentals Amidst Declining Profitability

Star Health & Allied Insurance continues to exhibit a complex fundamental profile. While the company boasts a robust long-term operating profit growth with a compound annual growth rate (CAGR) of 19.34%, recent quarterly results have been notably weak. The net sales have contracted sharply at an annual rate of -50.25%, signalling significant challenges in revenue generation. The latest quarter (Q2 FY25-26) saw profit before tax (PBT) excluding other income fall by 61.6% to ₹74.56 crores, while profit after tax (PAT) declined by 62.7% to ₹54.90 crores compared to the previous four-quarter average.

Return on equity (ROE) stands at a modest 7.2%, indicating limited profitability relative to shareholder equity. This combination of strong long-term profit growth but recent quarterly setbacks paints a mixed picture of the company’s quality, with concerns about near-term earnings momentum.

Valuation: Premium Pricing Amidst Weak Returns

The stock currently trades at ₹462.80, with a price-to-book (P/B) ratio of 3.7, which is considered expensive relative to its peers and historical averages. This premium valuation is difficult to justify given the company’s recent financial performance. Over the past year, Star Health’s stock has generated a negative return of -3.96%, underperforming the BSE500 benchmark and its sector peers, which have delivered positive returns in the range of 8.5% over the same period.

Moreover, the stock’s five-year and three-year returns have been disappointing, with a three-year return of -18.26% compared to the Sensex’s 40.02% gain. This persistent underperformance, coupled with a high valuation multiple, raises concerns about the stock’s attractiveness for value-conscious investors.

Financial Trend: Negative Quarterly Performance Clouds Outlook

The recent quarterly financials have been a key driver behind the downgrade. The sharp declines in PBT and PAT highlight operational challenges and margin pressures. Despite a strong institutional holding of 34.59%, which typically suggests confidence from sophisticated investors, the company’s earnings trajectory has been disappointing. The negative sales growth and profit contraction in the latest quarter contrast starkly with the company’s longer-term operating profit growth, indicating a possible cyclical or structural slowdown.

Investors should note that the company’s earnings have fallen by 38.2% over the past year, further emphasising the deteriorating financial trend. This weak earnings momentum undermines confidence in the stock’s near-term recovery potential.

Technical Analysis: Shift to Mildly Bearish Signals

The downgrade to Strong Sell was largely influenced by a shift in technical indicators from a sideways to a mildly bearish trend. Key technical metrics reveal a cautious outlook:

• MACD: Both weekly and monthly charts indicate a mildly bearish stance, suggesting weakening momentum.


• Bollinger Bands: Weekly and monthly readings also point to mild bearishness, signalling increased volatility and potential downward pressure.


• Moving Averages: The daily moving averages remain mildly bullish, indicating some short-term support.


• RSI: Both weekly and monthly Relative Strength Index readings show no clear signal, reflecting indecision among traders.


• KST and Dow Theory: Weekly KST is mildly bearish and monthly KST bearish, while Dow Theory weekly signals are mildly bearish and monthly show no trend.


• On-Balance Volume (OBV): Weekly OBV is mildly bearish, suggesting selling pressure, while monthly OBV shows no clear trend.

These mixed but predominantly negative technical signals have contributed to the downgrade, indicating that the stock may face further downward pressure in the near term despite some short-term bullish cues.

Stock Price and Market Performance

Star Health’s current price of ₹462.80 is below its 52-week high of ₹533.90 but comfortably above its 52-week low of ₹330.05. The stock has shown some resilience with a 1.71% gain on the day of the rating change, outperforming the Sensex’s marginal decline. However, the longer-term returns remain weak, with the stock underperforming the benchmark across multiple time frames, including one month (-3.71% vs. -0.53% Sensex), one year (-3.96% vs. 8.51%), and three years (-18.26% vs. 40.02%).

Institutional Confidence and Market Cap Considerations

Despite the downgrade, Star Health retains a market cap grade of 3, reflecting its mid-sized market capitalisation within the insurance sector. The company benefits from a relatively high institutional holding of 34.59%, which often signals confidence from professional investors who have the resources to analyse company fundamentals thoroughly. This institutional backing may provide some stability amid the current challenges.

However, the MarketsMOJO Mojo Score of 27.0 and a Mojo Grade of Strong Sell underscore the overall negative sentiment prevailing among analysts and technical models. The downgrade from a Sell to Strong Sell on 1 January 2026 reflects a consensus that the stock’s risks currently outweigh its potential rewards.

Conclusion: Cautious Approach Recommended

Star Health & Allied Insurance Company Ltd’s downgrade to Strong Sell is driven by a combination of deteriorating technical indicators, weak recent financial performance, and expensive valuation metrics. While the company’s long-term operating profit growth remains a positive, the sharp declines in quarterly profits and sales, coupled with persistent underperformance relative to benchmarks, raise significant concerns.

Investors should be wary of the mildly bearish technical signals that suggest further downside risk in the near term. The premium valuation relative to peers and the market, alongside disappointing earnings trends, make this stock a less attractive proposition at present. Those holding the stock may consider reviewing their positions in light of these developments, while prospective investors should exercise caution and seek alternatives with stronger fundamentals and technicals.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Saving Now →